{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:26Z","timestamp":1787004866739,"version":"build-2736575974"},"reference-count":65,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and can progress to serious complications, including metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Predisposing risk factors for MASH include obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. Patients with MASH often experience significant impairments in their health-related quality of life and other patient-reported outcomes (PROs), particularly in physical functioning domains, fatigue, and vitality. Incorporating PROs offers valuable insights into patients' perspectives on their symptoms, treatment efficacy, and overall well-being, thereby guiding more holistic and patient-centered care strategies. This review aims to investigate the utilization of patient-reported outcome measures (PROMs) in the context of MASLD and MASH care, identify which PROMs are employed, and summarize the outcomes reported.<\/jats:p>","DOI":"10.1055\/a-2435-2091","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T19:23:02Z","timestamp":1728328982000},"page":"210-220","source":"Crossref","is-referenced-by-count":8,"title":["Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.1055","volume":"45","author":[{"given":"Aurora","family":"Barber\u00e1","sequence":"additional","affiliation":[{"name":"The Global NASH Council, Washington, District of Columbia"},{"name":"Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trenton M.","family":"White","sequence":"additional","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish K.","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[{"name":"The Global NASH Council, Washington, District of Columbia"},{"name":"Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"The Global NASH Council, Washington, District of Columbia"},{"name":"Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain"},{"name":"CUNY Graduate School of Public Health and Health Policy, New York City, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[{"name":"The Global NASH Council, Washington, District of Columbia"},{"name":"Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia"},{"name":"Center for Outcomes Research in Liver Disease (CORLD), Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Z M Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"M E Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Z M Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"J V Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study","volume":"4","author":"C Fitzmaurice","year":"2018","journal-title":"JAMA Oncol"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12072-020-10038-w","article-title":"Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population","volume":"14","author":"M Sayiner","year":"2020","journal-title":"Hepatol Int"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.jhepr.2020.100171","article-title":"Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease","volume":"2","author":"P Golabi","year":"2020","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"A Mantovani","year":"2022","journal-title":"Gut"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/liv.14825","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis","volume":"41","author":"J M Schattenberg","year":"2021","journal-title":"Liver Int"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Z M Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"100525","DOI":"10.1016\/j.jhepr.2022.100525","article-title":"The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes","volume":"4","author":"Z Younossi","year":"2022","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","article-title":"A global research priority agenda to advance public health responses to fatty liver disease","volume":"79","author":"J V Lazarus","year":"2023","journal-title":"J Hepatol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-022-00228-y","article-title":"A multistakeholder approach to innovations in NAFLD care","volume":"3","author":"J M Schattenberg","year":"2023","journal-title":"Commun Med (Lond)"},{"issue":"01","key":"ref15","first-page":"e000083","article-title":"Effectiveness of integrated care interventions for patients with long-term conditions: a review of systematic reviews","volume":"4","author":"M HH Mansour","year":"2022","journal-title":"Integr Healthc J"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/hep.30125","article-title":"Patient-reported outcomes and the economic effects of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: the value proposition","volume":"68","author":"Z M Younossi","year":"2018","journal-title":"Hepatology"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3018(19)30345-5","article-title":"Patient-reported outcomes to enhance person-centred HIV care","volume":"7","author":"M Kall","year":"2020","journal-title":"Lancet HIV"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12981-024-00632-5","article-title":"Patient-reported outcomes and experiences of migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite treatment dispensation: the \u2018ASAP\u2019 study","volume":"21","author":"A K Arora","year":"2024","journal-title":"AIDS Res Ther"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/dme.14286","article-title":"A standard set of person-centred outcomes for diabetes mellitus: results of an international and unified approach","volume":"37","author":"J Nano","year":"2020","journal-title":"Diabet Med"},{"issue":"36","key":"ref20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"P G Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1310\/sci2003-167","article-title":"Definitions of quality of life: what has happened and how to move on","volume":"20","author":"M WM Post","year":"2014","journal-title":"Top Spinal Cord Inj Rehabil"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"e43086","DOI":"10.2196\/43086","article-title":"Patient-centered digital health records and their effects on health outcomes: systematic review","volume":"24","author":"M R Brands","year":"2022","journal-title":"J Med Internet Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1477-7525-8-89","article-title":"Patient reported outcomes: looking beyond the label claim","volume":"8","author":"L C Doward","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.cgh.2021.11.004","article-title":"Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global Non-Alcoholic Steatohepatitis (NASH)\/Non-Alcoholic Fatty Liver Disease (NAFLD) Registry","volume":"20","author":"Z M Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/hep.22868","article-title":"Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network","volume":"49","author":"K David","year":"2009","journal-title":"Hepatology"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"e000106","DOI":"10.1136\/bmjgast-2016-000106","article-title":"Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease","volume":"3","author":"M Sayiner","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Z M Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2036.2007.03426.x","article-title":"Health-related quality of life in patients with non-alcoholic fatty liver disease","volume":"26","author":"A A Dan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","author":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12325-018-0670-8","article-title":"Haptoglobin genotype and vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis in China: a multicenter, randomized, placebo-controlled trial design","volume":"35","author":"S Zang","year":"2018","journal-title":"Adv Ther"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s13063-022-06393-8","article-title":"Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Y Sun","year":"2022","journal-title":"Trials"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/jgh.15172","article-title":"Patient-reported outcomes in patients with non-alcoholic fatty liver disease: a narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis","volume":"36","author":"S Yamamura","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"e000069","DOI":"10.1136\/bmjgast-2015-000069","article-title":"Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)","volume":"3","author":"K S Chawla","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"e230033","DOI":"10.57264\/cer-2023-0033","article-title":"Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment","volume":"13","author":"D Aggio","year":"2024","journal-title":"J Comp Eff Res"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Z M Younossi","year":"1999","journal-title":"Gut"},{"issue":"05","key":"ref36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jval.2016.02.005","article-title":"Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C","volume":"19","author":"Z M Younossi","year":"2016","journal-title":"Value Health"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.cgh.2019.01.001","article-title":"Validation of Chronic Liver Disease Questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"17","author":"Z M Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12955-023-02195-x","article-title":"Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH","volume":"21","author":"J Fishman","year":"2023","journal-title":"Health Qual Life Outcomes"},{"key":"ref39","volume-title":"Development and Validation of CLDQ-MASH: A disease Specific Health Related Quality of Life Instrument for Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH)","author":"Z Younossi","year":"2024"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apt.17301","article-title":"Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study","volume":"57","author":"Y Yilmaz","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1357664","DOI":"10.3389\/fendo.2024.1357664","article-title":"Non-alcoholic fatty liver disease and coexisting depression, anxiety and\/or stress in adults: a systematic review and meta-analysis","volume":"15","author":"S Shea","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"09","key":"ref42","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/healthcare10091699","article-title":"Reduced quality of life in patients with non-alcoholic fatty liver disease may be associated with depression and fatigue","volume":"10","author":"J A Golubeva","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","article-title":"Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life","volume":"20","author":"Z M Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001084","article-title":"Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis","author":"Z M Younossi","year":"2024","journal-title":"Hepatology"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/apt.17598","article-title":"Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: a randomised trial","volume":"58","author":"M Romero-G\u00f3mez","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"09","key":"ref46","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Z M Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2024.04.008","article-title":"Assessment of fatigue and its impact in chronic liver disease","volume":"81","author":"Z M Younossi","year":"2024","journal-title":"J Hepatol"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40271-020-00485-w","article-title":"Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study","volume":"14","author":"L C Doward","year":"2021","journal-title":"Patient"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s41687-023-00589-5","article-title":"Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis","volume":"7","author":"J Twiss","year":"2023","journal-title":"J Patient Rep Outcomes"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/jmrs.421","article-title":"A review of the barriers to using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine cancer care","volume":"68","author":"H Nguyen","year":"2021","journal-title":"J Med Radiat Sci"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s11136-021-02999-8","article-title":"Patient-level barriers and facilitators to completion of patient-reported outcomes measures","volume":"31","author":"C Long","year":"2022","journal-title":"Qual Life Res"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1062860617745986","article-title":"Barriers and benefits to the use of patient-reported outcome measures in routine clinical care: a qualitative study","volume":"33","author":"L M Philpot","year":"2018","journal-title":"Am J Med Qual"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"e16140","DOI":"10.2196\/16140","article-title":"Adoption and attitudes of eHealth among people living with HIV and their physicians: Online Multicenter Questionnaire Study","volume":"8","author":"C Jacomet","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"g7818","DOI":"10.1136\/bmj.g7818","article-title":"Patient reported outcome measures in practice","volume":"350","author":"E C Nelson","year":"2015","journal-title":"BMJ"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jclinepi.2020.01.022","article-title":"Promoting effective use of patient-reported outcomes in clinical practice: themes from a \u201cMethods Tool kit\u201d paper series","volume":"122","author":"M D Brundage","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"06","key":"ref57","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s11136-019-02112-0","article-title":"Advancing the use of patient-reported outcomes in practice: understanding challenges, opportunities, and the potential of health information technology","volume":"28","author":"C J Hsiao","year":"2019","journal-title":"Qual Life Res"},{"key":"ref58","first-page":"382","article-title":"The eHealth trust model: a patient privacy research framework","volume":"257","author":"N Shen","year":"2019","journal-title":"Stud Health Technol Inform"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1365-2036.2005.02420.x","article-title":"A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis","volume":"21","author":"J B Schwimmer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2036.2009.04181.x","article-title":"Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease","volume":"31","author":"K D Kistler","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MPG.0b013e31826f2b8c","article-title":"Psychosocial outcomes for children with nonalcoholic fatty liver disease over time and compared with obese controls","volume":"56","author":"N Kerkar","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"e7871","DOI":"10.5812\/hepatmon.7871","article-title":"Paediatric non-alcoholic fatty liver disease: impact on patients and mothers' quality of life","volume":"13","author":"L Mazzone","year":"2013","journal-title":"Hepat Mon"},{"issue":"08","key":"ref63","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/hep4.1958","article-title":"Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV","volume":"6","author":"M Michel","year":"2022","journal-title":"Hepatol Commun"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/liv.15761","article-title":"Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: a cross-sectional study","volume":"44","author":"C W Wernberg","year":"2024","journal-title":"Liver Int"},{"issue":"12","key":"ref65","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.3390\/metabo13121174","article-title":"Lifestyle and quality of life of women diagnosed with hypothyroidism in the context of non-alcoholic fatty liver","volume":"13","author":"B Janota","year":"2023","journal-title":"Metabolites"},{"issue":"07","key":"ref66","doi-asserted-by":"crossref","first-page":"101066","DOI":"10.1016\/j.jhepr.2024.101066","article-title":"The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease","volume":"6","author":"Z M Younossi","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"05","key":"ref67","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S1092852922001043","article-title":"The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia","volume":"28","author":"M Y Jawad","year":"2023","journal-title":"CNS Spectr"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2435-2091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T18:34:14Z","timestamp":1749753254000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2435-2091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":65,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,6,12]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2435-2091","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10,7]]},"published":{"date-parts":[[2024,10,7]]}}}